P/E ratio for Takeda Pharmaceutical (TAK)
P/E ratio as of June 2023 (TTM): 19.2
According to Takeda Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.1997. At the end of 2022 the company had a P/E ratio of 23.9.
P/E ratio history for Takeda Pharmaceutical from 2009 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 23.9 | 42.32% |
| 2021 | 16.8 | -85.85% |
| 2020 | 119 | 196.62% |
| 2019 | 40.1 | 84.81% |
| 2018 | 21.7 | -40.77% |
| 2017 | 36.6 | -28.77% |
| 2016 | 51.4 | -255.86% |
| 2015 | -33.0 | -192.49% |
| 2014 | 35.7 | 23.28% |
| 2013 | 28.9 | 24.76% |
| 2012 | 23.2 | 85.08% |
| 2011 | 12.5 | 13.11% |
| 2010 | 11.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 32.4 | 68.87% | 🇺🇸 USA |
 Novartis NVS | 30.2 | 57.06% | 🇨🇭 Switzerland |
 Pfizer PFE | 7.41 | -61.43% | 🇺🇸 USA |
 Amgen AMGN | 14.7 | -23.31% | 🇺🇸 USA |
 Sanofi SNY | 17.9 | -6.62% | 🇫🇷 France |
 Merck MRK | 19.6 | 2.28% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.25 | -77.88% | 🇬🇧 UK |
 Seagen
SGEN | -59.2 | -408.37% | 🇺🇸 USA |
 Dr. Reddy's RDY | 23.9 | 24.44% | 🇮🇳 India |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.